Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

menarini-von heyden gmbh - metformin (metformin hydrochloride) - tablets film-coated - 1000mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

rottapharm ltd. - glucosamine (glucosamine sulfate) - powder for oral solution - 1500mg, (20), (30) sachets

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - lorlatinib - film coated tablets - lorlatinib 25 mg - lorlatinib - lorviqua is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk) positive.

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - lorlatinib - film coated tablets - lorlatinib 100 mg - lorlatinib - lorviqua is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk) positive.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - ritonavir, quantity: 100 mg - tablet, film coated - excipient ingredients: macrogol 3350; macrogol 400; sodium stearylfumarate; titanium dioxide; calcium hydrogen phosphate; sorbitan monolaurate; copovidone; hyprolose; purified talc; polysorbate 80; hypromellose; colloidal anhydrous silica - norvir (ritonavir) is indicated for use in combination with appropriate antiretriviral agents or as monotherapy if combination therapy is inappropriate, for the treatment of hiv-1 infection in adults and children aged 12 years and older. for persons with advanced hiv disease, the indication for ritonavir is based on the results for one study that showed a reduction in both mortality and aids defining clinical events for patients who received ritonavir. median duration of follow-up in this study was 6 months. the clinical benefit from ritonavir for longer periods of treatment is unknown. for persons with less advanced disease, the indication is based on changes in surrogate markers in controlled trials of up to 16 weeks in duration ( see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - lorlatinib, quantity: 25 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red; macrogol 3350; iron oxide black - lorviqua is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by a validated test.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - lorlatinib, quantity: 100 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; microcrystalline cellulose; calcium hydrogen phosphate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red; macrogol 3350; iron oxide black - lorviqua is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by a validated test.

United States - English - NLM (National Library of Medicine)

vertical pharmaceuticals, llc - calcium ascorbate (unii: 183e4w213w) (ascorbic acid - unii:pq6ck8pd0r), calcium threonate (unii: hbb4ypo93u) (calcium cation - unii:2m83c4r6zb), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), magnesium malate (unii: la9x9uja2z) (magnesium cation - unii:t6v3lhy838), zinc glycinate (unii: 681vjx72fe) (zinc cation - unii:13s1s8sf37), f - ascorbic acid 160 mg - corvite®fe should not be used by patients with a known hypersensitivity to any of the listed ingredients. all iron compounds are contraindicated in patients with hemochromatosis, hemosiderosis, or hemolytic anemias.

United States - English - NLM (National Library of Medicine)

vertical pharmaceuticals, llc - .beta.-carotene (unii: 01yae03m7j) (.beta.-carotene - unii:01yae03m7j), .alpha.-tocopherol succinate, d- (unii: lu4b53jyve) (.alpha.-tocopherol, d- - unii:n9pr3490h9), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), foli - .beta.-carotene 750 [iu] - corvite® multivitamin/multimineral supplements with iron are indicated for the distinctive nutritional requirements of persons being treated for vitamin deficiencies by a physician. corvite® multivitamin/multimineral supplements with iron should not be used by patients with a known history of hypersensitivity to any of the listed ingredients or as directed by a physician.